Acquisitions, Research System Adoption, Magazine Launches, Dividends, and FDA Approvals - Analyst Notes on Time, Thomson Reuters, Meredith, The New York Times and QIAGEN

NEW YORK, July 1, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Time Inc. (NYSE: TIME), Thomson Reuters Corporation (NYSE: TRI), Meredith Corporation (NYSE: MDP), The New York Times Company (NYSE: NYT) and QIAGEN NV (NASDAQ: QGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4299-100free.

Time Inc. Analyst Notes
On June 26, 2014, Time Inc. (Time) announced that its subsidiary, Grupo Expansión (GEx), will be acquired by Southern Cross subject to regulatory approvals. According to Joe Ripp, Chairman and CEO of Time, the Company is focusing on growing its core assets in the US and UK, and that GEx will have a better opportunity of maximizing its value under Southern Cross. Cesar Perez Barnes, Partner at Southern Cross Group, Mexico, said, "GEx is a successful multiplatform player with tremendous growth potential. We are confident that the company's strategic plans focused on technological innovation, its leading brands and its strong management team are the right building blocks to achieve continued success." The full analyst notes on Time are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/TIME/report.pdf

Thomson Reuters Corporation Analyst Notes
On June 26, 2014, the Intellectual Property & Science business of Thomson Reuters Corporation (Thomson Reuters) announced that its Thomson Reuters Converis was selected by the Singapore Management University (SMU) as its platform for holistic management of research lifecycle. According to the Company, Thomson Reuters Converis is a comprehensive system that provides pre-and-post award and open-access repository management supporting the entire spectrum of the research cycle. The Company added that with this selection, SMU is expected to gain insight into the efficiency and impact of its research based on real-time information integrated into one platform, with a holistic view of its research activity alongside research analytics which will lead to better informed decisions. Lau Kai Cheong, SMU Chief Information Officer and Vice President, Integrated Information Technology Services (IITS) said, "We are proud to be Asia's first university to use Converis for research management and look forward to gaining a comprehensive overview of our efforts that will aid us in furthering the global impact of our research programs." The full analyst notes on Thomson Reuters are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/TRI/report.pdf

Meredith Corporation Analyst Notes
On June 24, 2014, Meredith Corporation (Meredith) announced that in Spring of 2015, it will launch a new English-language magazine entitled "Parents Latina" targeting US Hispanic millennial mothers as demographic. The Company believes that the magazine will have tremendous appeal to the demographic craving for cultural relevance in the media written in English language. Meredith informed that the magazine will be published quarterly and is expected to have a guaranteed ratebase of 700,000. Tom Harty, Meredith National Media Group President said, "With the launch of Parents Latina, we are putting a new stake in the marketplace. We will leverage the power of Parents - the most respected brand in the lifestyle category focusing on moms - along with Meredith Hispanic Media and our 100-million-name database that includes 60 percent of all U.S. millennial women, to provide marketers with a powerful new platform to reach these very desirable consumers." The full analyst notes on Meredith are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/MDP/report.pdf

The New York Times Company Analyst Notes
On June 19, 2014, The Board of Directors of The New York Times Company declared a regular quarterly dividend of $0.04 per share on the Company's Class A and Class B common stock. According to the Company, the dividend is payable on July 31, 2014 to shareholders of record at the close of business on July 17, 2014. The full analyst notes on The New York Times are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/NYT/report.pdf

QIAGEN NV Analyst Notes
On June 18, 2014, QIAGEN NV (Qiagen) announced that its artus CMV RGQ MDx Kit for human cytomegalovirus (CMV) has been approved by the US Food and Drug Administration (FDA) under a full premarket approval (PMA), making it the only FDA- approved PCR-based assay test optimized for low-to-mid throughput testing of CMV. The Company stated that CMV testing is primarily used to aid in the management of solid organ transplant patients to assess viral load in response to antiviral drug therapy. Qiagen informed that the assay, with a turn-around time of approximately three hours, provides faster results than other PMA approved tests. Peer M. Schatz, CEO of QIAGEN, said "In addition to helping save lives with its clinically proven usefulness, the FDA-approved artus test creates economic value by reducing the time and money many labs and hospitals currently must spend validating lab-developed CMV tests and analyte-specific reagents." The full analyst notes on QIAGEN are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/QGEN/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review